Trade Benitec Biopharma Inc. - BNTC CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.1444 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 11.5478 |
| Open | 10.6178 |
| 1-Year Change | 269.58% |
| Day's Range | 10.6178 - 11.5278 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 11.2778 | 0.6600 | 6.22% | 10.6178 | 11.6378 | 10.6178 |
| Feb 20, 2025 | 11.5478 | 0.6400 | 5.87% | 10.9078 | 11.7378 | 10.7578 |
| Feb 19, 2025 | 11.0778 | -0.1100 | -0.98% | 11.1878 | 11.4778 | 11.0078 |
| Feb 18, 2025 | 11.2278 | -0.0600 | -0.53% | 11.2878 | 11.6278 | 10.2878 |
| Feb 14, 2025 | 11.2378 | 1.0600 | 10.41% | 10.1778 | 11.3278 | 10.0078 |
| Feb 13, 2025 | 9.7378 | -0.3400 | -3.37% | 10.0778 | 10.3278 | 9.6778 |
| Feb 12, 2025 | 10.2278 | -0.1500 | -1.45% | 10.3778 | 10.6778 | 10.0978 |
| Feb 11, 2025 | 10.3778 | -0.4300 | -3.98% | 10.8078 | 10.8978 | 10.3778 |
| Feb 10, 2025 | 10.9178 | 0.5000 | 4.80% | 10.4178 | 10.9278 | 10.4178 |
| Feb 7, 2025 | 10.4878 | -0.9700 | -8.47% | 11.4578 | 11.4578 | 10.4878 |
| Feb 6, 2025 | 11.4478 | 0.0700 | 0.62% | 11.3778 | 11.8278 | 11.1578 |
| Feb 5, 2025 | 11.7578 | -0.3900 | -3.21% | 12.1478 | 12.1578 | 11.2378 |
| Feb 4, 2025 | 12.1378 | 0.4100 | 3.50% | 11.7278 | 12.2778 | 11.7278 |
| Feb 3, 2025 | 11.7678 | 0.6900 | 6.23% | 11.0778 | 11.9178 | 11.0778 |
| Jan 31, 2025 | 11.3478 | 0.9300 | 8.93% | 10.4178 | 11.4578 | 10.4178 |
| Jan 30, 2025 | 10.7178 | -0.0900 | -0.83% | 10.8078 | 11.0178 | 10.5878 |
| Jan 29, 2025 | 10.7278 | 0.1400 | 1.32% | 10.5878 | 10.8578 | 10.5878 |
| Jan 28, 2025 | 10.6678 | -0.0100 | -0.09% | 10.6778 | 10.8978 | 10.4178 |
| Jan 27, 2025 | 10.7478 | -0.0300 | -0.28% | 10.7778 | 10.8278 | 10.5778 |
| Jan 24, 2025 | 10.6278 | 0.3300 | 3.20% | 10.2978 | 10.8378 | 10.2878 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Benitec Biopharma Inc. Company profile
About Benitec Biopharma Inc
Benitec Biopharma Inc is an Australia-based biotechnology company. The Company is focused on developing a therapeutic technology platform that combines ribonucleic acid (RNA) interference with gene therapy for the goal of silencing disease-causing genes from a single administration. The Company's technology, deoxyribonucleic acid (DNA)-directed RNA interference (ddRNAi), is used to develop product candidates in chronic and life-threatening human disease areas including orphan disease and infectious disease. Its pipeline includes BB-301, and BB-103. The Company's lead product candidate, BB-301, is used for the treatment of Oculopharyngeal Muscular Dystrophy (OPMD). Its BB-103 pipeline product is being developed for the treatment of chronic hepatitis B Virus infection.
Financial summary
BRIEF: For the six months ended 31 December 2021, Benitec Biopharma Inc revenues decreased 55% to $25K. Net loss increased 65% to $9.9M. Revenues reflect Licensing revenue segment decrease from $56K to $0K. Higher net loss reflects Research and development - Balancing val increase from $1.9M to $5.8M (expense), Stock-based Compensation in SGA increase from $105K to $349K (expense).
Equity composition
FY'05 is being restated for change in reporting GAAP to IFRS.04/2009, Rights Issue, 1 new share for every 3.142 shares held @ AUD .03 (Factor:1.000000). 04/2011, Rights Issue, 4 new shares for every 5 shares held @ AUD 0.02 (Factor:1.235330). 07/2013, 1-for-25 Reverse Stock split.
| Industry: | Biotechnology & Medical Research (NEC) |
3940 Trust Way
HAYWARD
CALIFORNIA 94545
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com